A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
Gerard J. Michel, insider at Delcath Systems

Gerard J. Michel Insider Information

Mr. Michel has over 30 years of experience in the pharmaceutical and medical technology industries across multiple functional areas. Prior to joining the Company, Mr. Michel was Chief Financial Officer of Vericel Corp., a biopharmaceutical company, since June 2014 where he was a key member of the management team which integrated a transformative acquisition and revised the company’s business model from a research focused company to a fully integrated, profitable commercial business. Mr. Michel also served as Chief Financial Officer and Vice President, Corporate Development of Biodel Inc., a specialty biopharmaceutical company focused on the treatment of diabetes, from November 2007 to May 2014, and Chief Financial Officer and Vice President of Corporate Development of NPS Pharmaceuticals Inc., a biopharmaceutical company focused on treatment options for patients with gastrointestinal and endocrine disorders, from August 2002 to November 2007. Prior to that, Mr. Michel was a Principal at Booz Allen Hamilton Inc. and also held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Mr. Michel holds an M.S. in Microbiology from the University of Rochester School of Medicine, an M.B.A. from the Simon School of Business, and a B.S. in both Biology and Geology from the University of Rochester.

What is Gerard J. Michel's net worth?

The estimated net worth of Gerard J. Michel is at least $604,147.20 as of July 20th, 2022. Mr. Michel owns 125,864 shares of Delcath Systems stock worth more than $604,147 as of August 15th. This net worth evaluation does not reflect any other investments that Mr. Michel may own. Additionally, Mr. Michel receives an annual salary of $683,820.00 as CEO at Delcath Systems. Learn More about Gerard J. Michel's net worth.

How old is Gerard J. Michel?

Mr. Michel is currently 59 years old. There are 3 older executives and no younger executives at Delcath Systems. Learn More on Gerard J. Michel's age.

What is Gerard J. Michel's salary?

As the CEO of Delcath Systems, Inc., Mr. Michel earned a total compensation package of $5,761,000.00 in 2020. Mr. Michel earned a salary of $112,500.00, options awards of $5,629,000.00, and other compensation of $19,500.00. Learn More on Gerard J. Michel's salary.

How do I contact Gerard J. Michel?

The corporate mailing address for Mr. Michel and other Delcath Systems executives is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. Delcath Systems can also be reached via phone at 212-489-2100 and via email at [email protected] Learn More on Gerard J. Michel's contact information.

Has Gerard J. Michel been buying or selling shares of Delcath Systems?

Over the course of the past ninety days, Gerard J. Michel has bought $249,999.72 in Delcath Systems stock. Most recently, on Wednesday, July 20th, Gerard J. Michel bought 62,814 shares of Delcath Systems stock. The stock was acquired at an average cost of $3.98 per share, with a total value of $249,999.72. Following the completion of the transaction, the chief executive officer now directly owns 125,864 shares of the company's stock, valued at $500,938.72. Learn More on Gerard J. Michel's trading history.

Who are Delcath Systems' active insiders?

Delcath Systems' insider roster includes Gerard Michel (CEO), John Purpura (COO), and Steven Salamon (Director). Learn More on Delcath Systems' active insiders.

Are insiders buying or selling shares of Delcath Systems?

During the last twelve months, Delcath Systems insiders bought shares 10 times. They purchased a total of 109,414 shares worth more than $585,884.72. The most recent insider tranaction occured on July, 20th when CEO Gerard J Michel bought 62,814 shares worth more than $249,999.72. Insiders at Delcath Systems own 16.8 % of the company. Learn More about insider trades at Delcath Systems.

Information on this page was last updated on 7/20/2022.

Gerard J. Michel Insider Trading History at Delcath Systems

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/20/2022Buy62,814$3.98$249,999.72125,864View SEC Filing Icon  
4/18/2022Buy2,000$6.37$12,740.0063,050View SEC Filing Icon  
4/8/2022Buy2,000$6.57$13,140.0061,050View SEC Filing Icon  
12/2/2021Buy23,200$8.61$199,752.00View SEC Filing Icon  
6/28/2021Buy6,250$11.93$74,562.5029,600View SEC Filing Icon  
6/25/2021Buy6,600$11.35$74,910.0029,600View SEC Filing Icon  
4/5/2021Buy15,500$12.88$199,640.0023,000View SEC Filing Icon  
12/11/2020Buy7,500$13.25$99,375.007,500View SEC Filing Icon  
See Full Table

Gerard J. Michel Buying and Selling Activity at Delcath Systems

This chart shows Gerard J Michel's buying and selling at Delcath Systems by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Delcath Systems Company Overview

Delcath Systems logo
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.50
Low: $4.48
High: $4.82

50 Day Range

MA: $4.06
Low: $3.62
High: $4.81

2 Week Range

Now: $4.50
Low: $3.49
High: $11.95


38,547 shs

Average Volume

28,374 shs

Market Capitalization

$38.69 million

P/E Ratio


Dividend Yield



The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!